CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

ABSTRACT:

Introduction

A substantial proportion of patients with Parkinson's disease (PD) have concomitant cognitive dysfunction. Identification of biomarker profiles that predict which PD patients have a greater likelihood for progression of cognitive symptoms is pressingly needed for future treatment and prevention approaches.

Methods

Subjects were drawn from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study, a large clinical trial that enrolled initially untreated PD patients. For the current study, Phase One encompassed trial baseline until just prior to levodopa administration (n = 403), and Phase Two spanned the initiation of levodopa treatment until the end of cognitive follow-up (n = 305). Correlations and linear mixed models were performed to d

SUBMITTER: Liu C 

PROVIDER: S-EPMC4603566 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature